Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy

RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives

(2019) Marco Infante et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Author Correction to: Denosumab: A Review in Postmenopausal Osteoporosis

(2018) Emma D. Deeks   DRUGS & AGING

THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis

(2018) Athanasios D Anastasilakis et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

(2018) Noopur Raje et al.   LANCET ONCOLOGY

Aptamers in the Therapeutics and Diagnostics Pipelines

(2018) Harleen Kaur et al.   Theranostics

Monoclonal antibodies for treating osteoporosis

(2017) Maria Felicia Faienza et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

(2017) H Ludwig et al.   LEUKEMIA

Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement

(2017) Panagiotis Anagnostis et al.   MATURITAS

Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis

(2017) Takako Suzuki et al.   Modern Rheumatology

The RANK/RANKL/OPG system in tumorigenesis and metastasis of cancer stem cell: potential targets for anticancer therapy

(2017) Mekonnen Sisay et al.   OncoTargets and Therapy

Generation of Aptamers from A Primer-Free Randomized ssDNA Library Using Magnetic-Assisted Rapid Aptamer Selection

(2017) Shih-Ming Tsao et al.   Scientific Reports

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

(2017) Henry G Bone et al.   Lancet Diabetes & Endocrinology

Strontium-loaded titania nanotube arrays repress osteoclast differentiation through multiple signalling pathways: In vitro and in vivo studies

(2017) Baoguo Mi et al.   Scientific Reports

Denosumab Reduces Cortical Porosity of the Proximal Femoral Shaft in Postmenopausal Women With Osteoporosis

(2016) Roger Zebaze et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates

(2016) P. D. Miller et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Aptamers as targeted therapeutics: current potential and challenges

(2016) Jiehua Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Postmenopausal Osteoporosis

(2016) Dennis M. Black et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab-associated hypocalcaemia: incidence, severity and patient characteristics in a tertiary hospital setting

(2016) Andrew Liem Hieu Huynh et al.   PHARMACOEPIDEMIOLOGY AND DRUG SAFETY

Postmenopausal osteoporosis

(2016) Richard Eastell et al.   Nature Reviews Disease Primers

Current approaches in SELEX: An update to aptamer selection technology

(2015) Mariia Darmostuk et al.   BIOTECHNOLOGY ADVANCES

Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis

(2015) S. Palacios et al.   CLIMACTERIC

Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials

(2015) Ana Boquete-Castro et al.   CLINICAL ORAL IMPLANTS RESEARCH

Peptide Aptamers: Development and Applications

(2015) Sergey Reverdatto et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Hypocalcaemia in patients with metastatic bone disease treated with denosumab

(2015) Jean-Jacques Body et al.   EUROPEAN JOURNAL OF CANCER

PET Imaging of Tenascin-C with a Radiolabeled Single-Stranded DNA Aptamer

(2015) O. Jacobson et al.   JOURNAL OF NUCLEAR MEDICINE

SDF-1 Inhibition Targets the Bone Marrow Niche for Cancer Therapy

(2014) Aldo M. Roccaro et al.   Cell Reports

Biology of the RANKL–RANK–OPG System in Immunity, Bone, and Beyond

(2014) Matthew C. Walsh et al.   Frontiers in Immunology

The Interplay between the Bone and the Immune System

(2013) Giorgio Mori et al.   Clinical & Developmental Immunology

Hematopoietic Stem and Progenitor Cell Mobilization in Mice and Humans by a First-in-Class Mirror-Image Oligonucleotide Inhibitor of CXCL12

(2013) A Vater et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Public Health Impact of Osteoporosis

(2013) J. A. Cauley   JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES

A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis

(2013) Luisella Cianferotti et al.   Therapeutic Advances in Musculoskeletal Disease

Single-stranded DNA (ssDNA) production in DNA aptamer generation

(2012) Citartan Marimuthu et al.   ANALYST

In vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imaging

(2012) Agnes Cibiel et al.   BIOCHIMIE

RNA-Based Therapeutics: Current Progress and Future Prospects

(2012) John C. Burnett et al.   CHEMISTRY & BIOLOGY

Role of RANK Ligand and Denosumab, a Targeted RANK Ligand Inhibitor, in Bone Health and Osteoporosis: A Review of Preclinical and Clinical Data

(2012) David W. Dempster et al.   CLINICAL THERAPEUTICS

Generating Aptamers by Cell-SELEX for Applications in Molecular Medicine

(2012) Mao Ye et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

The birth pangs of monoclonal antibody therapeutics

(2012) Lara Marks   mAbs

Impact of denosumab on the peripheral skeleton of postmenopausal women with osteoporosis

(2012) James A. Simon et al.   MENOPAUSE-THE JOURNAL OF THE NORTH AMERICAN MENOPAUSE SOCIETY

Bench to bedside: elucidation of the OPG–RANK–RANKL pathway and the development of denosumab

(2012) David L. Lacey et al.   NATURE REVIEWS DRUG DISCOVERY

Aptamers and Their Biological Applications

(2012) Kyung-Mi Song et al.   SENSORS

Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab

(2012) Athanasios Anastasilakis   Therapeutics and Clinical Risk Management

Aptamer-conjugated nanomaterials and their applications

(2011) Liu Yang et al.   ADVANCED DRUG DELIVERY REVIEWS

Advances and Perspectives in Cell-Specific Aptamers

(2011) Wei Sun et al.   CURRENT PHARMACEUTICAL DESIGN

Denosumab

(2011) Lesley J. Scott et al.   DRUGS

Effects of denosumab on fracture and bone mineral density by level of kidney function

(2011) Sophie A Jamal et al.   JOURNAL OF BONE AND MINERAL RESEARCH

PEGylated Anti-MUC1 Aptamer-Doxorubicin Complex for Targeted Drug Delivery to MCF7 Breast Cancer Cells

(2011) Lihan Tan et al.   MACROMOLECULAR BIOSCIENCE

Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association?

(2011) N. B. Watts et al.   OSTEOPOROSIS INTERNATIONAL

The RANKL Pathway and Denosumab

(2011) Robin K. Dore   RHEUMATIC DISEASE CLINICS OF NORTH AMERICA

Discovery and Development of Therapeutic Aptamers

(2010) P.R. Bouchard et al.   Annual Review of Pharmacology and Toxicology

Which fractures are most attributable to osteoporosis?

(2010) Amy H. Warriner et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial

(2010) Gareth J Morgan et al.   LANCET

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

(2010) S. Ferrari-Lacraz et al.   OSTEOPOROSIS INTERNATIONAL

New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis

(2010) J. C. Crockett et al.   OSTEOPOROSIS INTERNATIONAL

Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis

(2009) Steven R. Cummings et al.   NEW ENGLAND JOURNAL OF MEDICINE

Denosumab: Anti-RANKL antibody

(2009) Paul D. Miller   Current Osteoporosis Reports

SELEX with modified nucleotides

(2008) Anthony D Keefe et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Denosumab, a Fully Human Monoclonal Antibody to RANKL, Inhibits Bone Resorption and Increases BMD in Knock-In Mice That Express Chimeric (Murine/Human) RANKL*

(2008) Paul J Kostenuik et al.   JOURNAL OF BONE AND MINERAL RESEARCH